Ionis Pharmaceuticals, Inc. Common Stock insider trading
IONSfinancial statementsForm 4 filings on EDGAR420 transactions since Nov 16, 2024
From August 19, 2026 to November 16, 2026, 1 insider at Ionis Pharmaceuticals, Inc. Common Stock bought $148K of stock in the open market, and 2 sold $61K. Officers and directors accounted for $148K of purchases and $61K of sales. The last reported transaction was an open-market buy by Hayden Michael R on November 10, 2026.
The answer card and chart use the same period. Change the range above the chart to update both. Form 4 filings through November 13, 2026; awards, option exercises, tax withholding and gifts are excluded from these totals.
Stock price and insider activity
Daily price candles with insider purchases and sales directly beneath them on the same timeline. Bars show individual days; totals sum all days in the selected period.
Bought $148KSold $61KAug 19, 2026 – Nov 16, 2026
purchases above zero; sales below. Both use the transaction date and the same dollar scale. Hover, tap, or use arrow keys to inspect a date. Awards, exercises, tax withholding and gifts are excluded.
Dates with prices or insider activity are spaced evenly; empty weekends and holidays are omitted. Prices through Nov 13, 2026. Insider data through Nov 16, 2026. Prices are adjusted for splits; transaction values are reported dollars.
Every transaction
420 transactions from November 16, 2024 to November 16, 2026, newest first. Open-market purchases and sales are coloured; awards, exercises, tax withholding and gifts are grey and not counted.
| Traded | Insider | Role | Transaction | Shares | Price | Value | Held after | Filed |
|---|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Hayden Michael R | Director | open-market buyindirect | 5,000 | $29.64 | $148K | 27,000 | Nov 13, 2026 |
| Oct 16, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | open-market sale | 1,357 | $43.54 | $59K | 17,811 | Oct 19, 2026 |
| Oct 16, 2026 | Swayze Eric | EVP Research | open-market saleindirect | 53 | $43.54 | $2K | 390 | Oct 19, 2026 |
| Oct 15, 2026 | Devers Shannon L. | EVP, Chief Human Resources Ofc | option exercise | 2,820 | $0.00 | — | 19,168 | Oct 19, 2026 |
| Oct 15, 2026 | Swayze Eric | EVP Research | option exerciseindirect | 125 | $0.00 | — | 443 | Oct 19, 2026 |
| Aug 31, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | other | 110 | $51.31 | $6K | 60,128 | Sep 2, 2026 |
| Aug 31, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | other | 63 | $51.31 | $3K | 59,205 | Sep 2, 2026 |
| Aug 31, 2026 | Monia Brett P | Chief Executive Officer, Director | other | 98 | $51.31 | $5K | 242,760 | Sep 2, 2026 |
| Aug 31, 2026 | Birchler Brian | EVP, Corp and Development Ops | other | 58 | $51.31 | $3K | 102,883 | Sep 2, 2026 |
| Jul 31, 2026 | Hayden Michael R | Director | open-market buyindirect | 5,000 | $51.60 | $258K | 24,000 | Jul 31, 2026 |
| Jul 30, 2026 | Hayden Michael R | Director | open-market buyindirect | 15,000 | $53.38 | $801K | 19,000 | Jul 31, 2026 |
| Jul 15, 2026 | Herman Joan E | Director | option exercise | 5,220 | $0.00 | — | 51,306 | Jul 17, 2026 |
| Jul 15, 2026 | Berthelsen Spencer R | Director | option exercise | 5,220 | $0.00 | — | 161,233 | Jul 17, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | open-market sale10b5-1 | 5,536 | $83.58 | $463K | 75,018 | Jul 9, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | otherindirect | 15,000 | $0.00 | — | 15,000 | Jul 9, 2026 |
| Jul 7, 2026 | Bennett C Frank | EVP, Chief Scientific Officer | open-market sale10b5-1indirect | 15,000 | $85.46 | $1M | 0 | Jul 9, 2026 |
| Jul 7, 2026 | Diaz Allene M. | Director | option exercise | 10,111 | $47.11 | $476K | 13,922 | Jul 9, 2026 |
| Jul 7, 2026 | Diaz Allene M. | Director | open-market sale10b5-1 | 10,111 | $85.42 | $864K | 3,811 | Jul 9, 2026 |
| Jul 7, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | open-market sale10b5-1 | 362 | $84.30 | $31K | 22,096 | Jul 9, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | option exercise | 11,518 | $39.94 | $460K | 22,532 | Jul 6, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | open-market sale10b5-1 | 99 | $79.45 | $8K | 22,433 | Jul 6, 2026 |
| Jul 1, 2026 | Klein Joseph III | Director | open-market sale10b5-1 | 11,419 | $79.04 | $903K | 11,014 | Jul 6, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | option exerciseindirect | 3,866 | $56.78 | $220K | 8,535 | Jun 30, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | option exerciseindirect | 1,769 | $32.60 | $58K | 10,304 | Jun 30, 2026 |
| Jun 26, 2026 | Baroldi Joseph | EVP, Chief Business Officer | open-market sale10b5-1indirect | 5,635 | $80.16 | $452K | 4,669 | Jun 30, 2026 |
| Jun 26, 2026 | O'Neil Patrick R. | EVP CLO & General Counsel | open-market sale10b5-1 | 3,069 | $80.00 | $246K | 61,470 | Jun 30, 2026 |
| Jun 26, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | option exercise | 26,000 | $60.89 | $2M | 103,114 | Jun 30, 2026 |
| Jun 26, 2026 | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | open-market sale10b5-1 | 26,000 | $81.05 | $2M | 77,114 | Jun 30, 2026 |
| Jun 26, 2026 | Monia Brett P | Chief Executive Officer, Director | option exercise | 50,000 | $56.78 | $3M | 295,571 | Jun 26, 2026 |
| Jun 26, 2026 | Monia Brett P | Chief Executive Officer, Director | open-market sale10b5-1 | 50,000 | $80.59 | $4M | 245,571 | Jun 26, 2026 |
| Jun 25, 2026 | Monia Brett P | Chief Executive Officer, Director | option exercise | 21,072 | $32.60 | $687K | 266,643 | Jun 26, 2026 |
| Jun 25, 2026 | Monia Brett P | Chief Executive Officer, Director | open-market sale10b5-1 | 21,072 | $78.49 | $2M | 245,571 | Jun 26, 2026 |
| Jun 25, 2026 | Swayze Eric | EVP Research | open-market sale10b5-1 | 10,602 | $79.18 | $839K | 21,759 | Jun 26, 2026 |
| Jun 24, 2026 | Monia Brett P | Chief Executive Officer, Director | option exercise | 14,565 | $32.60 | $475K | 260,136 | Jun 26, 2026 |
| Jun 24, 2026 | Monia Brett P | Chief Executive Officer, Director | open-market sale10b5-1 | 14,565 | $78.41 | $1M | 245,571 | Jun 26, 2026 |
| Jun 15, 2026 | Berthelsen Spencer R | Director | option exercise | 8,000 | $24.42 | $195K | 164,013 | Jun 16, 2026 |
| Jun 15, 2026 | Berthelsen Spencer R | Director | open-market sale10b5-1 | 8,000 | $73.49 | $588K | 156,013 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | option exercise | 7,951 | $60.89 | $484K | 30,409 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | option exercise | 21,000 | $60.89 | $1M | 51,409 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | option exercise | 12,000 | $32.60 | $391K | 63,409 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | option exercise | 19,895 | $56.78 | $1M | 83,304 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | open-market sale10b5-1 | 41,004 | $73.09 | $3M | 42,300 | Jun 16, 2026 |
| Jun 12, 2026 | Kordasiewicz Holly B. | EVP, Chief Development Officer | open-market sale10b5-1 | 19,842 | $74.05 | $1M | 22,458 | Jun 16, 2026 |
| Jun 1, 2026 | Berthelsen Spencer R | Director | option exercise | 8,000 | $24.42 | $195K | 164,013 | Jun 3, 2026 |
| Jun 1, 2026 | Berthelsen Spencer R | Director | open-market sale10b5-1 | 8,000 | $75.67 | $605K | 156,013 | Jun 3, 2026 |
| May 14, 2026 | Monia Brett P | Chief Executive Officer, Director | option exercise | 3,220 | $32.60 | $105K | 245,882 | May 15, 2026 |
| May 14, 2026 | Monia Brett P | Chief Executive Officer, Director | open-market sale10b5-1 | 3,220 | $78.68 | $253K | 242,662 | May 15, 2026 |
| May 13, 2026 | Monia Brett P | Chief Executive Officer, Director | option exercise | 1,316 | $32.60 | $43K | 243,978 | May 15, 2026 |
| May 13, 2026 | Monia Brett P | Chief Executive Officer, Director | open-market sale10b5-1 | 1,316 | $78.01 | $103K | 242,662 | May 15, 2026 |
| May 4, 2026 | Loscalzo Joseph | Director | option exercise | 10,968 | $38.06 | $417K | 47,298 | May 6, 2026 |
Who the insiders are
Everyone who reported a transaction since November 16, 2024, by open-market value over twelve months. Shares held are after the insider’s latest directly held transaction.
| Insider | Role | Last transaction | Kind | Shares held | Bought, 12 months | Sold, 12 months | Sales under a plan |
|---|---|---|---|---|---|---|---|
| Monia Brett P | Chief Executive Officer, Director | Aug 31, 2026 | other | 242,760 | — | $30M (13) | 11 of 13 |
| Hougen Elizabeth L | EVP, Finance & CFO | Mar 17, 2026 | open-market sale | 82,660 | — | $18M (5) | 3 of 5 |
| Bennett C Frank | EVP, Chief Scientific Officer | Aug 31, 2026 | other | 60,128 | — | $17M (10) | 8 of 10 |
| Devers Shannon L. | EVP, Chief Human Resources Ofc | Oct 16, 2026 | open-market sale | 17,811 | — | $8M (13) | 11 of 13 |
| Loscalzo Joseph | Director | May 4, 2026 | option exercise | 47,298 | — | $6M (4) | 4 of 4 |
| Klein Joseph III | Director | Jul 1, 2026 | option exercise | 22,532 | — | $5M (10) | 10 of 10 |
| Swayze Eric | EVP Research | Oct 16, 2026 | open-market sale | 21,759 | — | $5M (9) | 5 of 9 |
| Diaz Allene M. | Director | Jul 7, 2026 | option exercise | 13,922 | — | $5M (4) | 4 of 4 |
| Kordasiewicz Holly B. | EVP, Chief Development Officer | Jul 7, 2026 | open-market sale | 22,096 | — | $5M (4) | 3 of 4 |
| Schneider Eugene | EVP, Chf Clinical Develop Ofcr | Jun 26, 2026 | option exercise | 103,114 | — | $4M (4) | 2 of 4 |
| Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | Apr 16, 2026 | open-market sale | 23,713 | — | $3M (4) | 2 of 4 |
| Herman Joan E | Director | Jul 15, 2026 | option exercise | 51,306 | — | $3M (2) | 0 of 2 |
| Baroldi Joseph | EVP, Chief Business Officer | Jun 26, 2026 | option exercise | 44,909 | — | $3M (11) | 7 of 11 |
| Wender Joseph H | Director | Dec 1, 2025 | open-market sale | 16,000 | — | $2M (2) | 2 of 2 |
| O'Neil Patrick R. | EVP CLO & General Counsel | Aug 31, 2026 | other | 59,205 | — | $2M (4) | 2 of 4 |
| Birchler Brian | EVP, Corp and Development Ops | Aug 31, 2026 | other | 102,883 | — | $1M (3) | 0 of 3 |
| Hayden Michael R | Director | Nov 10, 2026 | open-market buy | 54,298 | $1M (3) | — | — |
| Berthelsen Spencer R | Director | Jul 15, 2026 | option exercise | 161,233 | — | $1M (2) | 2 of 2 |
| Parshall B Lynne | Director | Apr 15, 2026 | open-market sale | 51,878 | — | $795K (3) | 3 of 3 |
| Geary Richard S | EVP, Chief Development Officer | Nov 6, 2025 | option exercise | 74,395 | — | — | — |
| Yang Michael J. | Director | Jan 15, 2026 | option exercise | 7,940 | — | — | — |
Questions
Are Ionis Pharmaceuticals, Inc. Common Stock insiders buying or selling?
Over the twelve months to November 16, 2026, 18 insiders at Ionis Pharmaceuticals, Inc. Common Stock sold $120M of stock in the open market, all by officers and directors, and 1 insider bought $1M, all by officers and directors. Net, insiders sold $119M. Only open-market purchases and sales are counted.
Who sold the most Ionis Pharmaceuticals, Inc. Common Stock stock in the last year?
Monia Brett P (Chief Executive Officer, Director) sold $30M in 13 open-market sales over the twelve months to November 16, 2026.
Do Ionis Pharmaceuticals, Inc. Common Stock executives sell under 10b5-1 plans?
79 of the 107 open-market sales in the last twelve months (74%) were reported as made under a Rule 10b5-1 trading plan, set up in advance. A sale under a plan is still counted as a sale.
What counts as insider buying here?
Only open-market purchases (Form 4 code P) and sales (code S) by officers, directors and 10% owners. Stock awards, option exercises, shares withheld for tax and gifts are listed in the table but never counted as buying or selling.
More on Ionis Pharmaceuticals, Inc. Common Stock
- Ionis Pharmaceuticals, Inc. Common Stock financial statements
- 1 tracked fund holding IONS
- Insider buying and selling across all companies
- These transactions as JSON
From Form 4, 4/A and 5 filings with the SEC. A record of insider transactions, not a recommendation.